NCT02906059View on ClinicalTrials.gov

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

AZD1775

DRUG

Irinotecan

Trial Locations (1)

10016

Laura and Isaac Perlmutter Cancer Center, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

NYU Langone Health

OTHER